Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06XDJ
|
|||
| Former ID |
DCL001172
|
|||
| Drug Name |
Clemizole
|
|||
| Synonyms |
Clemizole; 442-52-4; Histacur; Clemizol; Histakool; Lergopenin; Clemizolum; Depocural; 1-(p-Chlorobenzyl)-2-pyrrolidylmethylenebenzimidazole; 1-(4-Chlorobenzyl)-2-(pyrrolidin-1-ylmethyl)-1H-benzo[d]imidazole; NSC 46261; UNII-T97CB3796L; CHEBI:52140; CJXAEXPPLWQRFR-UHFFFAOYSA-N; T97CB3796L; 1-[(4-chlorophenyl)methyl]-2-(pyrrolidin-1-ylmethyl)benzimidazole; 1H-Benzimidazole, 1-[(4-chlorophenyl)methyl]-2-(1-pyrrolidinylmethyl)-; 1-(4-chlorobenzyl)-2-(pyrrolidin-1-ylmethyl)-1H-benzimidazole
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 1 | [1] | |
| Company |
Eiger BioPharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H20ClN3
|
|||
| Canonical SMILES |
C1CCN(C1)CC2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)Cl
|
|||
| InChI |
1S/C19H20ClN3/c20-16-9-7-15(8-10-16)13-23-18-6-2-1-5-17(18)21-19(23)14-22-11-3-4-12-22/h1-2,5-10H,3-4,11-14H2
|
|||
| InChIKey |
CJXAEXPPLWQRFR-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 442-52-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
99695, 615231, 4445364, 8151794, 10522977, 11110952, 11110953, 11466255, 11467375, 11485930, 15347485, 29221937, 47216959, 47216960, 47810952, 47959954, 48110645, 48334694, 49698395, 50100200, 50104284, 57304882, 57321456, 79754667, 85209562, 85788561, 87906851, 90341639, 103826182, 104301595, 106178634, 117463367, 124662137, 124879655, 124879656, 124879657, 125823529, 127635999, 134974845, 134986591, 136351847, 137005449, 142245913, 160671857, 162224660, 170497650, 172915197, 179225225, 184531234, 185985216
|
|||
| ChEBI ID |
CHEBI:52140
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepatitis C virus Non-structural 4B (HCV NS4B) | Target Info | Modulator | [1], [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J Infect Dis. 2010 Jul 1;202(1):65-74. | |||
| REF 2 | The Hepatitis C virus (HCV) NS4B RNA binding inhibitor, clemizole, is highly synergistic with HCV protease inhibitors | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.